Another study — the largest to date — has shown that anti-malaria drugs hydroxychloroquine and chloroquine have no benefit in treating COVID-19, in fact have a negative effect on patient survival and are associated with an increase in ventricular arrhythmias. Read More

A leading COVID-19 vaccine candidate has shown promise as being safe and effective in humans and produced an immune response against the coronavirus, according to preliminary data from a phase 1 trial of 108 healthy adults in China. Read More

NIH Friday confirmed preliminary remdesivir trial data showing that the drug delivered a median recovery time of 11 days compared with 15 on placebo, establishing it as the standard of care for patients with moderate to severe disease. Read More

The FDA added morphine sulfate and epinephrine to the list of compounded drugs under the agency’s temporary policy that allows outsourcing facilities to produce the drugs during the COVID-19 pandemic. Read More

TriNetX is partnering with the FDA’s Sentinel Operations Center at the Harvard Pilgrim Health Care Institute (HPHCI) to monitor priority drugs used for treating hospitalized COVID-19 patients. Read More

Enrollment for a large, global trial of chloroquine and hydroxychloroquine for the prevention of COVID-19 is getting under way in the United Kingdom. Read More

AstraZeneca has nabbed an HHS contract worth up to $1.2 billion to speed development and production of the University of Oxford’s promising COVID-19 vaccine candidate. The deal also would lock in the distribution of 300 million doses of the vaccine for the U.S. Read More